SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

Summary Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed as a novel
class of anti-hyperglycaemic drugs, have been shown to significantly improve metabolic …

Sodium-glucose cotransporter2 (SGLT2) inhibitors have a reno-protective effect in diabetic
kidney disease. However, the detailed mechanism remains unclear. In this study, human …

Given that the increase in the aging population has grown into one of the largest public
health issues, inflammation and oxidative stress, which are closely associated with the aging …

The rapid increase in both the lifespan and proportion of older adults is accompanied by the
unprecedented rise in age-associated chronic diseases, including sarcopenia and obesity …

Skeletal muscle is one of the largest organs in the body and the largest protein repository.
Mitochondria are the main energy-producing organelles in cells and play an important role …

Diabetic nephropathy (DN), the leading cause of end-stage renal disease, is the most
significant microvascular complication of diabetes and poses a severe public health concern …

Excessive accumulation of advanced glycation end products (AGEs) contributes to
autophagy interruption on podocytes and insufficient autophagy on podocytes is …

Atherosclerosis-caused cardiovascular diseases (CVD) are the leading cause of mortality in
type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 (SGLT2) inhibitors are …

Diabetic kidney disease (DKD) is one of the most important comorbidities for patients with
diabetes, and its incidence has exceeded one tenth, with an increasing trend. Studies have …